Articles tagged with Tumor Cells
A new test, PLA test, evaluates the effectiveness of cancer vaccines by detecting tumor antigens presented on MHC molecules. The test has shown promising results in identifying glioma tumors and melanoma cells with specific antigens.
Researchers found that collagen cross-links play a crucial role in regulating stromal stiffness and determining tumor cell metastatic fate. The study identified two types of collagen cross-links, HLCC and LCC, which are associated with different levels of tumor growth and spread.
Chronic inflammatory conditions are directly associated with several types of cancer, but the cellular mechanisms behind this link were unclear. An international team of scientists has identified a multistep process showing how these cancers develop, providing potential therapeutic targets for halting tumor cell formation.
Researchers employed a 'Big Bang' model to trace the origins of colorectal cancer cells, revealing clues to why tumor cells become good or bad and potential ways to stop them before they start growing. The study highlights the importance of understanding the early stages of tumor development to prevent cancer.
Researchers at Griffith University have discovered that mitochondria can transfer genetic material between healthy and cancerous cells, leading to rapid proliferation of tumour cells. This finding has implications for our understanding of human biology and may shed light on other diseases with defective mitochondrial DNA.
Researchers discovered that cells with low levels of profilin 1 protein in breast tumors have increased capacity to metastasize and invade other tissues. The protein regulates the formation of invasive structures called invadopodia, which play a critical role in tumor invasion and metastasis.
Researchers discovered that gene NR2F1 induces dormancy in tumor cells when activated, preventing rapid growth and division. Combining azacytidine and retinoic acid significantly increased NR2F1 activity, leading to improved therapeutic outcomes.
Researchers at CNIC identified the molecular mechanism regulating transport of Rac1 between nucleus and cytoplasm. Sustained presence of Rac1 in nucleus promotes nuclear deformation to facilitate cell migration through confined spaces. The study provides potential targets for future therapies.
Researchers propose a novel approach to cancer therapy by subtly hardening cancer cells to prevent metastasis. They've identified a compound, 4-HAP, that shows promise in fighting pancreatic cancer.
Researchers discovered that Twist1, a developmental regulator, primes cells for stem-cell-like properties when activated transiently. This leads to cellular plasticity and regenerative potential. Conversely, chronic Twist1 activity promotes invasive, non-proliferative phenotypes in tumor cells.
A study led by St. Jude Children's Research Hospital scientists has identified the population of white blood cells that tumors use to enhance growth and suppress the disease-fighting immune system. Monocytes are primarily responsible for T cell suppression around tumors.
Researchers found a mutated region in human mantle cell lymphoma DNA that disables programmed cell death. Cells with this mutation grow uncontrollably, but a new therapy approach targets the ubiquitin ligase responsible for the defect.
Researchers at Centenary Institute used a super-resolution microscope to study the role of DPP9 in cell movement. They found that inhibiting this enzyme can slow down living cancer cells and prevent tumors from growing or spreading.
Researchers at the Buck Institute discovered that senescent cells secrete PDGF-AA, which accelerates wound closure and heals wounds normally. This finding suggests that cellular senescence may play a beneficial role in human health throughout the lifespan.
Researchers develop a new approach to customize nuclear medicine treatment for cancer, using targeted alpha therapy with customized radiolabeled antibody cocktails. This method has great potential for treating various diseases, including those with disseminated tumor cells.
Researchers at Dana-Farber Cancer Institute have discovered an effective treatment for small cell lung cancer using the compound THZ1, which targets tumor cells' basic survival machinery. Clinical trials are underway to test its safety and efficacy in human patients.
Geneticists identified double minutes in glioblastoma cells with specific oncogenes, which amplify malignancy and give cancer cells an adaptive edge. The presence of these mini-chromosomes is detected in most aggressive cancers.
Researchers found malignant mesothelioma tumors to be polyclonal, resulting from the growth of multiple mutant cells. This challenges the long-held belief that cancers are caused by a single cell mutation.
A new study identifies TET1 as a master regulator in cancer progression by silencing tumor suppressor genes. Adding TET1 back to cancer cells reactivates these genes, reducing abnormal proliferation.
A study by MD Anderson Cancer Center researchers found that the enzyme PKM2 controls cell division, promoting tumor cell proliferation. PKM2's role in regulating cytokinesis was also identified as crucial for brain tumor development and malignant tumor progression.
Scientists have developed a novel delivery platform that allows for the inhibition of microRNA activity, leading to controlled cancer growth. The breakthrough uses a peptide with low-pH induced transmembrane structure to target tumor cells, providing a promising new model for cancer therapeutics.
Researchers have discovered that tumor cells secrete exosomes containing proteins capable of transforming neighboring cells into tumor cells, promoting tumor growth. Dicer protein is identified as a key factor in this process and may serve as a biomarker or therapeutic target.
Researchers from Berkeley Lab have developed a new method to create immortal human mammary epithelial cells with normal genomes. This breakthrough could facilitate the examination of cell immortalization as it occurs in cancer development and potentially lead to new therapeutic approaches.
Researchers have successfully triggered the self-destruct process in lung cancer cells, paving the way for a new treatment approach that leaves healthy cells unharmed. The breakthrough was achieved using a combination of two drugs, TRAIL and a CDK9 inhibitor, which altered the molecular switches in the cell suicide process.
Researchers identified CD44 as a potential marker to select patients unresponsive to Sorafenib, a common liver cancer treatment. Patients with a less differentiated mesenchymal phenotype expressing CD44 tend to resist Sorafenib's action, highlighting the need for alternative therapies.
A personalized cellular therapy called CTL019 achieved complete remission in 27 of 30 patients with relapsed or refractory acute lymphoblastic leukemia, with 78% remaining alive six months post-treatment. The treatment involves infusing engineered immune cells that target cancer cells.
Researchers found that nuclear factor kappa B (NF-kB) enables cancer cells to evade the immune system by suppressing genes that inhibit the immune response. Inhibiting NF-kB may make tumor cells more vulnerable to elimination by the immune system.
Researchers have identified a class of chemical compounds that make cancer cells more sensitive to chemotherapeutic drugs. The compounds, referred to as T8, specifically target the protein disulfide isomerase enzyme and induce programmed cell death in rapidly dividing cancer cells.
A study found that postpartum mice develop metastatic disease due to dying tumor cells triggering anti-inflammatory cytokines that promote wound healing. Mice lacking a receptor for macrophage clearance of dying cells did not develop metastasis, highlighting potential targets for limiting postpartum breast cancer severity.
Researchers found that cancer cells decorate their surfaces with glycans that can promote or inhibit cancer progression depending on the stage of the disease. The immune system may be a double-edged sword in cancer, with certain immune cell receptors binding to these glycans producing opposite outcomes.
A UK study has identified a novel molecule called Arylquin 1 that induces Par-4 secretion from normal cells, killing cancer cells while leaving normal cells unharmed. The researchers found that Arylquin 1 binds to vimentin, displacing the Par-4 for secretion and may be useful in inhibiting tumor metastasis.
Scientists have discovered a unique biochemical connection between cell membranes and mitochondria, regulating cellular energy production. This finding has implications for understanding diseases linked to mitochondrial dysfunction, including cancer and neurodegenerative disorders.
A new mouse model reveals that high levels of Notch1 can transform osteoblasts into cancerous cells, leading to osteogenic sarcoma. This study supports the hypothesis that Notch activating mutations can act as a common triggering mechanism in bone cancer.
Researchers developed a new method to detect malignant brain tumors using a handheld Raman scanner, which can identify cancerous cells with high accuracy. The technique has the potential to improve surgical outcomes and reduce tumor recurrence rates.
Researchers at Massachusetts General Hospital found that CTC clusters are associated with poor prognosis and metastatic potential. The presence of CTC clusters in the blood of cancer patients may identify a novel target for therapy.
Scientists discovered that the Hippo pathway, a tumor suppressor pathway, senses abnormal chromosome numbers in cells and triggers cell cycle arrest. This pathway prevents progression into cancer by halting the proliferation of tetraploid cells with double the number of chromosomes.
Brain tumors use a stealth approach to evade the body's defense forces by coating their cells with extra amounts of galectin-1, a protein that evades detection by the early-warning immune system. Blocking this protein could potentially help patients by enabling the innate immune system to recognize and attack early-stage cancer growth.
Researchers at MD Anderson Cancer Center have discovered that protein ZEB1 helps breast cancer cells repair DNA damage caused by radiation therapy, making them more resistant to treatment. This finding has significant implications for the development of new treatments targeting ZEB1 and other proteins involved in radioresistance.
Researchers found that HSF1 activates a transcriptional program in both cancer cells and stromal cells, fueling malignant processes. HSF1 activation is associated with poor patient outcomes in breast and lung cancers, making it a potential biomarker for predicting tumor progression.
Researchers at The Wistar Institute discovered that mice lacking TRAP-1 protein live longer lives with fewer age-related illnesses. TRAP-1 is an important regulator of metabolism and has been shown to regulate energy production in mitochondria, organelles that generate chemically useful energy for the cell.
Researchers at University of São Paulo identified INXS RNA, which modulates BCL-X gene and induces programmed cell death. Local injections of plasmid containing INXS reduced subcutaneous malignant tumors by 10-fold in mice.
Researchers discovered two distinct molecular clocks operating at different stages of tumor growth, with implications for chemotherapy resistance and prognosis. The study used single-cell genome sequencing to profile thousands of cells, providing insights into genomic diversity and its potential clinical applications.
Researchers at Université catholique de Louvain successfully identified a family of pharmaceutical compounds that prevent the formation of human tumor metastasis. The study found that mitochondria can promote cell migration leading to metastasis, which can be blocked by specific antioxidants.
A study by the University of Pennsylvania School of Medicine identified an enzyme called FBP1 that regulates metabolism and restrains energy production in cells. The enzyme is missing from all kidney tumor tissue, leading to rapid cell growth. This discovery may lead to personalized approaches for treating clear cell renal cell carcino...
Researchers used game theory to study tumor cell cooperation and found that within certain ranges of mutation rates, critical transitions occur in energy metabolic strategies. This switch in tactics may make tumors vulnerable to disruption, potentially ideal for clinicians to test new therapies.
A new study has identified a previously unknown mechanism used by neurons to survive, which is also hijacked by brain cancer cells. The discovery may lead to new investigations of brain cancer treatments and provide insight into Parkinson's disease.
Recent research suggests that antioxidant supplements and foods may not reduce cancer risk, but instead accelerate cancer development. The study proposes that antioxidants accumulate at distant sites in cells, leaving tumor-promoting ROS relatively unperturbed, which can stimulate cancer cell growth.
Researchers at University College London have discovered a way to block the movement of cancer cells by targeting chemical signals that trigger their transformation into an invasive, liquid-like state. This breakthrough could lead to innovative techniques to stop cancer cells from spreading and causing secondary tumours.
Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered over 40 genes that predict melanoma aggressiveness and distinguish it from other cancers with poor prognoses. These genes are involved in the formation of endosomes, which play a crucial role in tumor cell behavior.
Mathematicians develop models to describe cell migration and tumor invasion, as well as dispersal patterns in species. The studies reveal the existence and uniqueness of traveling waves in malignant tumor invasion and show how fitness-dependent dispersal conveys advantages towards ideal free distribution in populations.
Researchers have discovered a protein called focal adhesion kinase (FAK) that plays a crucial role in ovarian cancer cell growth. A network of signals generated by osteopontin and FAK controls spheroid growth, making it a potential target for new therapies.
Researchers discovered that switching off and then reactivating the Pax5 gene can reverse cancer in a common childhood leukemia model. Restoring its function enables normal blood cell development and cures the disease. The findings offer a promising new strategy for treating leukemia with fewer side effects.
Scientists create ultra-small nanoparticles that can bind to cancer cells using camel antibody fragments, potentially revolutionizing tumor detection. The particles successfully evade the human immune system and reach diseased cells under conditions similar to those in patients' bodies.
The study reveals that each glioblastoma tumor contains individual cells from multiple cancer sub-types, and that the distribution of these cells varies from tumor to tumor. This heterogeneity may contribute to drug resistance and disease recurrence, highlighting the need for personalized treatment approaches.
A Cornell research team has developed a new microfluidic device to isolate and study the most aggressive cancer cells. The device separates these cells from less aggressive ones, enabling researchers to analyze molecular changes that contribute to metastasis.
Researchers developed a new test that assesses metastatic risk by identifying specific cell types in tumor microenvironments. The test was more accurate than existing methods in predicting distant tumor spread and showed promise in tailoring therapy for breast cancer patients.
Scientists have discovered a potential new target for cancer immunotherapy, peptide antibodies that deplete immune-suppressing MDSCs without harming other vital cells. The treatment showed promising results in preclinical experiments, shrinking tumors and improving outcomes.
Researchers at Georgetown University Medical Center have developed a new technique to grow both normal and cancer cells indefinitely, transforming basic cancer research. This breakthrough allows for faster development of certain types of breast cancer in mice, with tumors behaving similarly to human breast cancer.
Researchers found that patients with tumor cells in their blood after surgery had a higher risk of relapse and poorer survival rates. The presence and count of tumor cells also predicted disease-free survival, with those having 5 or more CTCs at higher risk of recurrent disease.
A Phase I study of an experimental antibody produced at St. Jude Children's Research Hospital found tumors shrank or disappeared in some patients with advanced neuroblastoma, and disease progression was temporarily halted in 15 children.